BTIG analyst Ryan Zimmerman lowered the firm’s price target on Alcon (ALC) to $92 from $100 and keeps a Buy rating on the shares following the Q2 earnings report. Alcon was wrong in assuming that the broader surgical eye care market would recover in fiscal 2025 and has damaged its credibility by missing expectations the past few quarters, the analyst tells investors in a research note. Alcon, is now removing any assumption of a recovery in market growth in FY25, which BTIG says is “appropriate.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Alcon’s Strong EPS Performance and Promising Outlook Justify Buy Rating Despite Revenue and EBIT Challenges
- Closing Bell Movers: La-Z-Boy down 24% after earnings miss
- Alcon’s Strategic Moves: Q2 2025 Results and STAAR Acquisition
- Alcon down 7% at $84.00 after Q2 results and guidance
- Alcon reports Q2 EPS 76c, consensus 72c